Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?
checkpoint inhibitors
checkpoint inhibitory therapy
inflammatory indices
polymyalgia rheumatica
Journal
Reumatologia
ISSN: 0034-6233
Titre abrégé: Reumatologia
Pays: Poland
ID NLM: 20130190R
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
02
2020
accepted:
20
04
2020
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
21
7
2020
Statut:
ppublish
Résumé
The existence of polymyalgia rheumatica (PMR) with normal inflammatory indices at the time of diagnosis still represents a diagnostic conundrum. According to the literature, some patients with PMR following immune checkpoint inhibitory therapy had normal values of both erythrocyte sedimentation rate and C-reactive protein concentrations at the time of diagnosis. In this short communication we investigated the possibility that in some patients with PMR the main pathogenic mechanism is constituted by inhibition of some checkpoints, such as programmed death receptor-1, programmed death ligand 1, and "cytotoxic" lymphocyte antigen 4. In these patients, the pathogenetic mechanisms underlying PMR can act much more upstream than commonly suggested. Also, we addressed the question of whether these patients should be considered as affected by PMR-like syndromes or by PMR subset.
Identifiants
pubmed: 32684653
doi: 10.5114/reum.2020.96549
pii: 96549
pmc: PMC7362269
doi:
Types de publication
Journal Article
Langues
eng
Pagination
184-186Informations de copyright
Copyright: © 2020 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Semin Arthritis Rheum. 2018 Jun;47(6):907-910
pubmed: 29191375
J Rheumatol. 2006 Apr;33(4):703-8
pubmed: 16583473
J Rheumatol. 2020 Feb;47(2):166-175
pubmed: 31308203
Reumatismo. 2018 Mar 27;70(1):10-17
pubmed: 29589398
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
J Autoimmun. 2017 May;79:1-3
pubmed: 28256368
Semin Arthritis Rheum. 2004 Apr;33(5):289-93
pubmed: 15079759
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E970-E979
pubmed: 28115719
Nat Rev Rheumatol. 2018 Oct;14(10):569-579
pubmed: 30171203
Autoimmun Rev. 2012 Nov;12(1):22-30
pubmed: 22878274
Ann Rheum Dis. 2005 Apr;64(4):626-9
pubmed: 15769919
JAMA. 2016 Jun 14;315(22):2442-58
pubmed: 27299619
Arthritis Rheumatol. 2019 Mar;71(3):468-475
pubmed: 30281202
Rheumatology (Oxford). 2019 May 1;58(5):921-923
pubmed: 30649507
J Leukoc Biol. 2018 Mar;103(3):565-575
pubmed: 28848042
RMD Open. 2019 Apr 25;5(1):e000906
pubmed: 31168414
Ann Rheum Dis. 2012 Apr;71(4):484-92
pubmed: 22388996
Reumatologia. 2018;56(1):1-2
pubmed: 29686435
Joint Bone Spine. 2017 Mar;84(2):233-234
pubmed: 27133763
Eur J Immunol. 2001 Aug;31(8):2357-61
pubmed: 11500818
J Rheumatol. 2019 Dec;46(12):1552-1555
pubmed: 31787593
Ann Rheum Dis. 2019 Jul;78(7):e70
pubmed: 29760158
Indian J Med Res. 2017 May;145(5):593-600
pubmed: 28948949
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692